Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [DEA #186F]
 AGENCY: Drug Enforcement Administration (DEA), Justice.
 ACTION: Notice of final 2000 aggregate production quotas.
 SUMMARY: This notice establishes final 2000 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA). The DEA has taken into consideration comments received in response to a notice of the proposed revised aggregate production quotas for 2000 published July 19, 2000 (65 FR 44836).
 EFFECTIVE DATE: September 25, 2000.
 FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.


SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations. On July 19, 2000, a notice of the proposed revised 2000 aggregate production quotas for certain controlled substances in Schedules I and II was published in the 
                    **Federal Register**
                    (65 FR 44836). All interested parties were invited to comment on or object to these proposed aggregate production quotas on or before August 18, 2000. Several companies and one individual commented that the revised aggregate production quotas for amphetamine, codeine (for sale), dextropropoxyphene, dihydrocodeine, hydrocodone (for sale), hydromorphone, meperidine, methadone intermediate, methylphenidate, opium, oxycodone (for sale), oxycodone (for conversion), oxymorphone, pentobarbital, phenylacetone, and tetrahydrocannabinols were insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and for the establishment and maintenance of reserve stocks. DEA has taken into consideration the above comments along with the relevant 1999 year-end inventories, initial 2000 manufacturing quotas, 2000 export requirements, and actual and projected 2000 sales. Based on this information, the DEA has adjusted the final 2000 aggregate production quotas for 4-methoyxamphetamine, amphetamine, dihydrocodeine, hydromorphone, meperidine, methamphetamine, oxycodone (for sale), oxycodone (for conversion), oxymorphone and pentobarbital to meet the legitimate needs of the United States. Regarding codeine (for sale), dextropropoxyphene, hydrocodone (for sale), methadone intermediate, opium, methylphenidate, phenylacetone and tetrahydrocannabinols, the DEA has determined that no adjustments of the aggregate production quotas are necessary to meet the 2000 estimated medical, scientific, research and industrial needs of the United States. Therefore, under the authority vested in the Attorney General by Section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations, the Deputy Administrator hereby orders that the final 2000 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows: Basic class
Established final 2000 quotasSchedule I:2,5-Dimethoxyamphetamine
10,501,0002,5-Dimethoxy-4-ethylamphetamine (DOET)
23-Methylfentanyl
143-Methylthiofentanyl
23,4-Methylenedioxyamphetamine (MDA)
203,4-Methylenedioxy-N-ethylamphetamine (MDEA)
303,4-Methylenedioxymethamphetamine (MDMA)
203,4,5-Trimethoxyamphetamine
24-Bromo-2,5-Dimethoxyamphetamine (DOB)
24-Bromo-2,5-Dimethoxyphenethylamine (2 CB)
24-Methoxyamphetamine
251,0004-Methylaminorex
34-Methyl-2,5-Dimethoxyamphetamine (DOM)
25-Methoxy-3,4-Methylenedioxyamphetamine
2Acetyl-alpha-methylfentanyl
2Acetyldihydrocodeine
2Acetylmethadol
7Allylprodine
2Alphacetylmethadol
7Alpha-ethyltryptamine
2( print page 57625)Alphameprodine
2Alphamethadol
2Alpha-methylfentanyl
2Alpha-methylthiofentanyl
2Aminorex
7Benzylmorphine
2Betacetylmethadol
2Beta-hydroxy-3-methylfentanyl
2Beta-hydroxyfentanyl
2Betameprodine
2Betamethadol
2Betaprodine
2Bufotenine
2Cathinone
9Codeine-N-oxide
2Diethyltryptamine
2Difenoxin
10,000Dihydromorphine
508,000Dimethyltryptamine
3Gamma-hydroxybutyric acid
15,000,000Heroin
2Hydroxypethidine
2Lysergic acid diethylamide (LSD)
63Mescaline
7Methaqualone
17Methcathinone
9Morphine-N-oxide
2N,N-Dimethylamphetamine
7N-Ethyl-1-Phenylcyclohexylamine (PCE)
5N-Ethylamphetamine
7N-Hydroxy-3,4-Methylenedioxyamphetamine
2Noracymethadol
2Norlevorphanol
2Normethadone
7Normorphine
7Para-fluorofentanyl
2Pholcodine
2Propiram
415,000Psilocybin
2Psilocyn
2Tetrahydrocannabinols
115,000Thiofentanyl
2Trimeperidine
2Schedule II:1-Phenylcyclohexylamine
121-Piperidinocyclohexanecarbonitrile (PCC)
10Alfentanil
8,000Alphaprodine
2Amobarbital
12Amphetamine
10,958,000Cocaine
251,000Codeine (for sale)
43,248,000Codeine (for conversion)
52,384,000Dextropropoxyphene
121,017,000Dihydrocodeine
244,000Diphenoxylate
931,000Ecgonine
36,000Ethylmorphine
12Fentanyl
300,000Glutethimide
2Hydrocodone (for sale)
21,417,000Hydrocodone (for conversion)
20,700,000Hydromorphone
1,409,000Isomethadone
12Levo-alphacetylmethadol (LAAM)
12Levomethorphan
2Levorphanol
27,000Meperidine
10,168,000Metazocine
1Methadone (for sale)
8,347,000Methadone (for conversion)
0Methadone Intermediate
9,503,000( print page 57626)Methamphetamine
2,104,000850,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,225,000 grams for methamphetamine for conversion to a Schedule III product; and, 29,000 grams for methamphetamine (for sale)Methylphenidate
14,957,000Morphine (for sale)
14,706,000Morphine (for conversion)
97,410,000Nabilone
2Noroxymorphone (for sale)
25,000Noroxymorphone (for conversion)
3,813,000Opium
720,000Oxycodone (for sale)
35,850,000Oxycodone (for conversion)
602,000Oxymorphone
353,000Pentobarbital
24,037,000Phencyclidine
41Phenmetrazine
2Phenylacetone
10Secobarbital
22Sufentanil
1,700Thebaine
45,444,000
 The Deputy Administrator further orders that aggregate production quotas for all other Schedules I and II controlled substances included in Sections 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations remain at zero. The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 13132, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment. The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 
                    *et seq*. The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. Aggregate production quotas apply to approximately 200 DEA registered bulk and dosage form manufacturers of Schedules I and II controlled substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis. Dated: September 15, 2000. Julio F. Mercado, Deputy Administrator.


[FR Doc. 00-24554  Filed 9-22-00; 8:45 am] BILLING CODE 4410-09-M